Diabetologie und Stoffwechsel 2019; 14(S 01): S10
DOI: 10.1055/s-0039-1688133
ePoster
Digitalisierung und neue Technologien
Georg Thieme Verlag KG Stuttgart · New York

Impact of a digital platform (PDMone) on glycemic control as support of the specialist diabetes care

A Reichel
1   Universitätsklinikum 'Carl Gustav Carus' der Technischen Universität Dresden, Medizinische Klinik und Poliklinik III, Dresden, Germany
,
J Moecks
2   bioMcon – Bio-Math-Consulting GmbH, bioMcon – Bio-Math-Consulting GmbH, Mannheim, Germany
,
S Brenner
3   UMIT – Private Universität für Gesundheitswissenschaften, Medizinische Informatik und Technik GmbH, Institut für Management und Ökonomie im Gesundheitswesen, Hall in Tirol, Austria
,
B Kulzer
4   Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM), Forschungsinstitut der Diabetes-Akademie Bad Mergentheim (FIDAM), Bad Mergentheim, Germany
,
R Daikeler
5   Internistische Gemeinschaftspraxis, Diabetologische Schwerpunktpraxis, Sinsheim, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
07 May 2019 (online)

Also available at
 

Background:

The present study investigates the clinical use of an advanced digital management platform providing support for diabetology practices in managing type-2-diabetes patients (T2DM). This analysis addresses the temporal patterns of HbA1c-development of T2DM-patients requiring changes in insulin therapy (initiation or intensification).

Methods:

The visit-based digital platform PDMone (Roche Diabetes Care) was employed in clinical routine in nine German diabetology practices. In total, 123 patients were observed for 9+months. Data records included all customary anamnestic and lab information plus HbA1c target-setting. The analysis in clinical subgroups relied on the individual time-to-target achievement.

Results:

The mean baseline HbA1c-level of 9.1%(± 1.8) decreased by 1.7%(± 2.1) at last measurement. Regression analysis showed a significant contribution of high baseline HbA1c-levels on the extent of this reduction. The duration to achieving the HbA1c-target was in the median 251 days in all patients, but was 148 days in patients only recently referred to a diabetologist (p = 0.0118). HbA1c-target achievers (47%) decreased their HbA1c by 3.1%(± 2.1) vs. 1.2%(± 1.3) for non-achievers (53%), there was no difference in baseline demographics. Both decreases were highly significant (p < 0.001) with no significant elevation of BMI for either group. The development of clinical lab parameters was more favorable for achievers.

Conclusion:

Records of HbA1c-target management from the routine use of PDMone were successfully analyzed, providing clinically relevant details of the temporal HbA1c-development. Target-based management led to a solid rate of achievers with massive HbA1c-decreases and favorable development of clinically relevant lab parameters. PDMone supported guideline adherence, contributed to improved quality while saving time and resources.